I agree. Wish I had never bought into this stock. They have had a lot of red flags over the years. Wall Street doesn't like their business model even, regarding the licensing deals. Unfortunately at this point I think its prudent to hold rather than take a massive loss, not going to get much worse than this - other than a complete write down.
He also has 50 #$%$ that just slam the stocks he doesn't like. Did the same with GNCA which was and is a VICAL competitor. Regardless if he is right on either, he is just another troll on these useless message boards.
Why would she have even ever tried to create value if her severance package was more than 99% of people make in a lifetime? What a waste. No-talent hack who was hired because of her gender.
I want to know how at 2:30 pm yesterday, hours before the release, all of a sudden the robo-traders knew to start selling the #$%$ out of these shares. Intuition? Doubtful. Someone knew that they were going to miss estimates for the first time in over a year, and the SEC and everyone else ignores it. I could see if the drop was post-earnings, but the stock already dropped almost 5% before the call, for no apparent reason, unless of course you already knew they were going to report a miss.
Too bad nobody else does. Robo traders trading off Biotech in general today so companies with actual good results get punished. Total nonsense.
If you think you are going to lose all your money owning Gilead, you are crazy. Don't listen to the morons on these message boards.
They are not going to spend a warchest of cash on something that they believe will not be a blockbuster that is in their wheelhouse. They are still generating a ton of cash flow. The story is interesting, victims of their own success. People have no problem paying 100x earnings for Facebook that sells nothing but Ads, inflates the numbers of actual regular users, and who will clearly never catch up to their multiple, but with healthcare stocks, you need a pipeline and products. At this price you are basically buying any future earnings from the Hep C drugs and getting the pipeline for free, plus the chance at a late stage developed drug added to the pipeline from future M&A.
What the fact that they have some debt? They spent $11B or something on Pharmassett. They still have 12 billion in cash and can afford to spend $8B on a company they want. You are just spouting out BS rumors, that you know nothing about, unless of course you are on the Board of Sanofi and just want to give out their M&A strategy for free.
Dude, where are you coming up with this? Gilead can spend as much as they want on something. They certainly are not going to spend $8B on something that is not yet recommended for approval. They also are not going to buy something that will become the secondary treatment for anything liver related so its probably more significant than it seems.
Its not going to $650 a share on an Adcomm recommendation. At most you would see the company just to a $5B market cap which is still a huge jump for a day. Unless its followed by a massive takeout.